Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 273.0
(-0.73%)
JPY 273.0
(-0.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 1.07 Billion JPY | -60.72% |
| 2021 | 2.74 Billion JPY | -77.88% |
| 2020 | 12.42 Billion JPY | 17.42% |
| 2019 | 10.57 Billion JPY | 47.7% |
| 2018 | 7.16 Billion JPY | 9.3% |
| 2017 | 6.55 Billion JPY | 17.62% |
| 2016 | 5.57 Billion JPY | -2.93% |
| 2015 | 5.73 Billion JPY | -16.62% |
| 2014 | 6.88 Billion JPY | -4.2% |
| 2013 | 7.18 Billion JPY | 43.47% |
| 2012 | 5 Billion JPY | 11.55% |
| 2011 | 4.48 Billion JPY | 55.54% |
| 2010 | 2.88 Billion JPY | -54.16% |
| 2009 | 6.29 Billion JPY | 41.57% |
| 2008 | 4.44 Billion JPY | 12.49% |
| 2007 | 3.95 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q3 | 740 Million JPY | 55.14% |
| 2023 Q2 | 477 Million JPY | -16.9% |
| 2023 Q1 | 574 Million JPY | -4.65% |
| 2022 Q3 | 655 Million JPY | 80.94% |
| 2022 FY | 1.07 Billion JPY | -60.72% |
| 2022 Q4 | 602 Million JPY | -8.09% |
| 2022 Q1 | -540 Million JPY | 50.0% |
| 2022 Q2 | 362 Million JPY | 167.04% |
| 2021 Q1 | 2 Billion JPY | 0.0% |
| 2021 Q2 | -524 Million JPY | -126.11% |
| 2021 FY | 2.74 Billion JPY | -77.88% |
| 2021 Q4 | -1.08 Billion JPY | -146.08% |
| 2021 Q3 | 2.34 Billion JPY | 547.33% |
| 2020 FY | 12.42 Billion JPY | 17.42% |
| 2020 Q1 | 3.11 Billion JPY | -28.22% |
| 2020 Q3 | 3.64 Billion JPY | -9.87% |
| 2020 Q2 | 4.03 Billion JPY | 29.48% |
| 2019 Q2 | 1.02 Billion JPY | -48.19% |
| 2019 FY | 10.57 Billion JPY | 47.7% |
| 2019 Q1 | 1.97 Billion JPY | -22.33% |
| 2019 Q3 | 2.08 Billion JPY | 103.79% |
| 2019 Q4 | 4.34 Billion JPY | 108.16% |
| 2018 Q4 | 2.54 Billion JPY | 44.25% |
| 2018 Q3 | 1.76 Billion JPY | 102.17% |
| 2018 Q1 | 1.58 Billion JPY | -37.07% |
| 2018 Q2 | 873.02 Million JPY | -44.83% |
| 2018 FY | 7.16 Billion JPY | 9.3% |
| 2017 Q3 | 1.49 Billion JPY | 56.5% |
| 2017 Q2 | 957.32 Million JPY | -18.5% |
| 2017 Q1 | 1.17 Billion JPY | -49.82% |
| 2017 FY | 6.55 Billion JPY | 17.62% |
| 2017 Q4 | 2.51 Billion JPY | 67.84% |
| 2016 Q4 | 2.34 Billion JPY | 73.35% |
| 2016 FY | 5.57 Billion JPY | -2.93% |
| 2016 Q3 | 1.35 Billion JPY | 91.45% |
| 2016 Q2 | 705.3 Million JPY | -44.31% |
| 2016 Q1 | 1.26 Billion JPY | -41.2% |
| 2015 Q2 | 959.43 Million JPY | -29.37% |
| 2015 Q1 | 1.35 Billion JPY | -51.19% |
| 2015 Q4 | 2.15 Billion JPY | 58.49% |
| 2015 FY | 5.73 Billion JPY | -16.62% |
| 2015 Q3 | 1.35 Billion JPY | 41.65% |
| 2014 Q4 | 2.78 Billion JPY | 72.81% |
| 2014 Q3 | 1.61 Billion JPY | 42.38% |
| 2014 Q1 | 1.69 Billion JPY | -30.68% |
| 2014 Q2 | 1.13 Billion JPY | -33.39% |
| 2014 FY | 6.88 Billion JPY | -4.2% |
| 2013 Q1 | 1.21 Billion JPY | -26.73% |
| 2013 FY | 7.18 Billion JPY | 43.47% |
| 2013 Q2 | 1.32 Billion JPY | 9.76% |
| 2013 Q4 | 2.44 Billion JPY | 43.54% |
| 2013 Q3 | 1.7 Billion JPY | 28.33% |
| 2012 Q4 | 1.65 Billion JPY | 34.87% |
| 2012 Q2 | 916.4 Million JPY | -20.59% |
| 2012 FY | 5 Billion JPY | 11.55% |
| 2012 Q1 | 1.15 Billion JPY | -6.58% |
| 2012 Q3 | 1.22 Billion JPY | 33.8% |
| 2011 Q3 | 1.11 Billion JPY | 13.6% |
| 2011 Q2 | 983.16 Million JPY | 155.79% |
| 2011 FY | 4.48 Billion JPY | 55.54% |
| 2011 Q1 | 384.36 Million JPY | -59.45% |
| 2011 Q4 | 1.23 Billion JPY | 10.6% |
| 2010 Q3 | 862.65 Million JPY | 24.78% |
| 2010 Q1 | 409.48 Million JPY | -81.47% |
| 2010 Q4 | 947.82 Million JPY | 9.87% |
| 2010 FY | 2.88 Billion JPY | -54.16% |
| 2010 Q2 | 691.36 Million JPY | 68.84% |
| 2009 Q4 | 2.21 Billion JPY | 0.14% |
| 2009 Q3 | 2.2 Billion JPY | 50.26% |
| 2009 Q2 | 1.46 Billion JPY | 48.7% |
| 2009 Q1 | 987.78 Million JPY | -27.96% |
| 2009 FY | 6.29 Billion JPY | 41.57% |
| 2008 FY | 4.44 Billion JPY | 12.49% |
| 2008 Q4 | 1.37 Billion JPY | 0.0% |
| 2007 FY | 3.95 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 97.787% |
| Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 99.951% |
| Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 99.426% |
| Shionogi & Co., Ltd. | 369.08 Billion JPY | 99.708% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | 69.527% |
| Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 98.888% |
| Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 97.177% |
| Eisai Co., Ltd. | 586.41 Billion JPY | 99.816% |
| Morishita Jintan Co., Ltd. | 5.99 Billion JPY | 82.011% |
| Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 98.634% |
| Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 97.928% |
| Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | 92.017% |
| Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | 86.056% |
| Tsumura & Co. | 68.81 Billion JPY | 98.432% |
| Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 97.11% |
| Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | 95.648% |
| Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 98.674% |
| Fuji Pharma Co., Ltd. | 16.51 Billion JPY | 93.467% |
| Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 97.85% |
| KYORIN Holdings, Inc. | 51.4 Billion JPY | 97.901% |
| Daito Pharmaceutical Co.,Ltd. | 9.83 Billion JPY | 89.033% |
| SymBio Pharmaceuticals Limited | 4.41 Billion JPY | 75.539% |
| MedRx Co., Ltd | 26 Million JPY | -4050.0% |
| Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | 86.556% |
| Solasia Pharma K.K. | 337 Million JPY | -220.178% |
| Modalis Therapeutics Corporation | -731 Thousand JPY | 147706.019% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 30.66 Billion JPY | 96.481% |
| Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 98.014% |
| Cyfuse Biomedical K.K. | 37.74 Million JPY | -2758.733% |
| Toho Holdings Co., Ltd. | 112.98 Billion JPY | 99.045% |
| Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | 83.749% |